RDP Pharma AG is a privately held biotech company focused on drug discovery and development of therapeutic and delivery technologies, notably the PromptDegrader™ platform for targeted degradation of intrinsically disordered region (IDR) proteins. Its pipeline includes an orally available HPV E7 degrader and additional projects such as CROMOC (drug delivery module) and CP201 (an oral alkyletherlipid candidate for cancer treatment).
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Platform for targeted protein degradation of intrinsically disordered protein regions, with AI-enabled, rational design of small-molecule degraders for oncology, neurology, immune response, virology and aging.
c-Myc-targeted degradation therapeutics
Development of c-Myc degraders and c-Myc/RNA disruptors, with orally available small-molecule candidates and preclinical development up to IND-enabling.
Alkyl ether lipid CP201
Development of an orally available alkyl ether lipid against cancer, with preclinical and non-clinical data, Phase 1 readiness and potential further development as an antiviral.
Drug Delivery Module (DDM) / CROMOC
Proprietary delivery module for the cellular transport of therapeutics and biomolecules, with improved tissue selectivity, high payload capacity, and use across various cancer types.
Knowledge
No knowledge articles yet
Once RDP Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.